Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu)Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin

Amgen

Status and phase: Completed; Phase 2; Phase 1

Conditions: Parkinson's Disease

Treatments: Biological: Liatermin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00111982

20030160

Details and patient eligibility

About

The purpose of this study is to determine long-term efficacy of continuous IPu liatermin infusion administered with concomitant standard anti-Parkinsonian therapy.

Enrollment: 34 patients

Sex: All

Ages: 35 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: - Completion of the 20020168 protocol

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

34 participants in 1 patient group

Liatermin

Experimental group

Description:

Bilateral continuous infusion of liatermin for up to 24 months.

Treatment:

Biological: Liatermin